1 Introduction

Malaria is a life-threatening disease caused by Plasmodium parasites, which are transmitted to humans through the bites of infected female Anopheles mosquitoes. The most common and deadly species responsible for malaria in humans are Plasmodium falciparum and Plasmodium vivax. Malaria remains a significant global health challenge, particularly in sub-Saharan Africa, where it causes substantial morbidity and mortality. The disease's complex lifecycle, involving both human and mosquito hosts, complicates efforts to control and eliminate it (Nikolaeva et al., 2015; Olotu et al., 2017; Draper et al., 2018).

Vector management and vaccine development are critical components of malaria control and elimination strategies. Vector control, which includes interventions such as insecticide-treated bed nets, indoor residual spraying, and environmental management, has been instrumental in reducing malaria transmission in many regions (Karunamoorthi, 2011; Wilson et al., 2020). However, the emergence of insecticide resistance among mosquito populations poses a significant threat to the sustainability of these interventions (Wilson et al., 2020).

On the other hand, vaccine development offers a promising complementary approach to malaria control. Despite the challenges posed by the parasite's complex lifecycle and its ability to evade the immune system, significant progress has been made in developing vaccines targeting various stages of the parasite's lifecycle (Holder, 1990; Dhanawat et al., 2010; Draper et al., 2018). Transmission-blocking vaccines, pre-erythrocytic vaccines, and blood-stage vaccines are among the strategies being explored to provide long-term protection against malaria (Wang et al., 2009; Nikolaeva et al., 2015; Ogeto et al., 2020).

The study aims to provide a comprehensive overview of recent advances in vector management and vaccine development for malaria control. By synthesizing findings from multiple research studies, this study will highlight the progress made, the challenges encountered, and the future directions in these critical areas. The scope of this study includes an examination of the latest vector control strategies, the development and clinical trials of various malaria vaccines, and the integration of these approaches into broader malaria elimination efforts. Through this study, we seek to inform and guide future research and policy decisions aimed at achieving the ultimate goal of malaria eradication.

2 Overview of Malaria

2.1 Explanation of malaria and its causative agents

Malaria is a life-threatening disease caused by Plasmodium parasites, which are transmitted to humans through the bites of infected female Anopheles mosquitoes. There are five species of Plasmodium that cause malaria in humans: Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi. Among these, P. falciparum is the most deadly and prevalent, particularly in Africa (Wang et al., 2009; Crompton et al., 2010). The complex lifecycle of Plasmodium involves both human and mosquito hosts, making the development of effective control measures challenging (Wang et al., 2009).

2.2 Transmission cycle

The transmission cycle of malaria involves several stages. When an infected mosquito bites a human, it injects sporozoites into the bloodstream. These sporozoites travel to the liver, where they mature and multiply. After a period of development, the parasites enter the bloodstream and infect red blood cells, leading to the symptomatic phase of the disease. Some of these parasites develop into sexual forms called gametocytes, which are taken up by mosquitoes during a blood meal. Inside the mosquito, the gametocytes undergo further development, eventually forming sporozoites that migrate to the mosquito's salivary glands, ready to infect another human host (Wang et al., 2009; Crompton et al., 2010; Theisen et al., 2017).

2.3 Global burden

Malaria remains a significant global health issue, particularly in sub-Saharan Africa, where it is a leading cause of morbidity and mortality. The disease disproportionately affects children under five and pregnant women. Despite extensive control efforts, including the use of insecticide-treated nets and indoor residual spraying, malaria continues to pose a substantial public health challenge. The development of effective vaccines and novel vector control strategies is crucial for reducing the global burden of malaria (Benelli and Beier, 2017; Ogeto et al., 2020; Wilson et al., 2020). The RTS,S vaccine, targeting the pre-erythrocytic stage of the parasite, is one of the most advanced candidates and has shown partial efficacy in clinical trials (Crompton et al., 2010; Ogeto et al., 2020).

In summary, malaria is a complex disease caused by Plasmodium parasites, with a lifecycle involving both human and mosquito hosts. The global burden of malaria remains high, necessitating continued efforts in vaccine development and vector control to achieve significant reductions in disease incidence and mortality.

3 Advances in Vector Management

3.1 Insecticide-treated nets (ITNs) and indoor residual spraying (IRS)

Insecticide-treated nets (ITNs) and indoor residual spraying (IRS) are two primary vector control strategies used to combat malaria. ITNs involve the use of mosquito nets treated with insecticides, primarily pyrethroids, which are safe for prolonged contact with human skin. IRS, on the other hand, involves spraying the interior walls of homes with insecticides to kill mosquitoes that rest indoors. Combining ITNs with IRS has been shown to enhance malaria control, especially in areas where mosquitoes have developed resistance to pyrethroids (Pluess et al., 2010; Protopopoff et al., 2015; Pryce et al., 2022).

Studies have demonstrated that adding IRS to ITNs can significantly reduce malaria prevalence and incidence. For instance, a study in Northern Tanzania found that combining IRS with ITNs reduced the density of Anopheles mosquitoes by 84% and the entomological inoculation rate (EIR) by 90% compared to ITNs alone (Protopopoff et al., 2015). Similarly, research in Mozambique showed that IRS with non-pyrethroid insecticides, such as pirimiphos-methyl, in addition to ITNs, reduced malaria vector densities and human exposure to malaria vectors (Chaccour et al., 2018; Wagman et al., 2021).

3.2 Biological control methods

Biological control methods involve the use of natural predators, pathogens, or competitors to control mosquito populations. These methods are environmentally friendly and can be integrated with other vector control strategies. One promising biological control method is the use of larvivorous fish, which feed on mosquito larvae in water bodies, thereby reducing the adult mosquito population. Another approach is the use of entomopathogenic fungi, which infect and kill mosquitoes (Beier et al., 2008).

The integration of biological control methods with ITNs and IRS can enhance the overall effectiveness of malaria control programs. For example, the use of larvivorous fish in combination with ITNs and IRS has been shown to reduce mosquito densities and malaria transmission rates (Beier et al., 2008). Additionally, the use of entomopathogenic fungi can target insecticide-resistant mosquito populations, providing an alternative control measure in areas where chemical insecticides are less effective (Beier et al., 2008).

3.3 Genetic control techniques

Genetic control techniques involve the manipulation of mosquito genes to reduce their ability to transmit malaria or to reduce their population size. One such technique is the release of genetically modified mosquitoes that are sterile or have a reduced lifespan. Another approach is the use of gene drive systems, which spread genetic modifications rapidly through mosquito populations (Beier et al., 2008).

Recent advances in genetic control techniques have shown promise in reducing malaria transmission. For instance, the release of sterile male mosquitoes has been used to suppress mosquito populations in several pilot studies. Additionally, gene drive systems have been developed to spread genes that confer resistance to malaria parasites or reduce mosquito fertility (Beier et al., 2008). These genetic control techniques can be integrated with ITNs and IRS to provide a comprehensive approach to malaria vector management.

In conclusion, advances in vector management, including the combination of ITNs and IRS, biological control methods, and genetic control techniques, offer promising strategies for enhancing malaria control. These approaches can be tailored to local conditions and integrated into national malaria control programs to achieve sustainable reductions in malaria transmission and incidence.

4 Vaccine Development for Malaria

4.1 Types of malaria vaccines

Malaria vaccines can be broadly categorized into three types: pre-erythrocytic, blood-stage, and transmission-blocking vaccines. Pre-erythrocytic vaccines target the sporozoite stage of the Plasmodium parasite before it infects liver cells. Blood-stage vaccines aim to prevent the parasite from multiplying within red blood cells, thereby reducing the severity of the disease. Transmission-blocking vaccines are designed to prevent the parasite from being transmitted from humans to mosquitoes, thereby interrupting the cycle of infection (Wilby et al., 2012; Arora et al., 2021; Nadeem et al., 2022).

4.2 RTS,S/AS01 (mosquirix)

RTS,S/AS01, also known as Mosquirix, is the most advanced malaria vaccine to date. It is a pre-erythrocytic vaccine that targets the circumsporozoite protein (CSP) of Plasmodium falciparum. The vaccine has undergone extensive clinical trials, demonstrating modest efficacy in preventing clinical malaria in children. In Phase 3 trials, the vaccine showed an efficacy of about 36% in children aged 5-17 months and about 26% in infants aged 6-12 weeks (Wilby et al., 2012; Regules et al., 2016; Arora et al., 2021). Despite its limited efficacy, RTS,S/AS01 has been approved by the World Health Organization (WHO) and is being integrated into routine immunization programs in several African countries (Figure 1) (Mahmoudi and Keshavarz, 2017; Arora et al., 2021; Nadeem et al., 2022).

4.3 Novel vaccine candidates

In addition to RTS,S/AS01, several novel vaccine candidates are under development. These include vaccines targeting different stages of the Plasmodium life cycle and employing various immunological strategies. For instance, some candidates focus on enhancing the immunogenicity and duration of protection by optimizing the dosing schedule. A study on fractional third and fourth doses of RTS,S/AS01 showed improved immunogenicity and sustained high protection against malaria (Regules et al., 2016). Other candidates are exploring the combination of vaccines with antimalarial drugs to enhance efficacy and provide broader protection (Seidlein et al., 2019). Additionally, research is ongoing to develop vaccines that can be co-administered with other pediatric vaccines without compromising safety or immunogenicity (Valéa et al., 2018).

5 Integrated Approaches to Malaria Control

5.1 Combining vector management and vaccination

Integrated approaches to malaria control emphasize the combination of vector management and vaccination to achieve more effective and sustainable outcomes. Integrated Vector Management (IVM) is a key strategy that involves the rational use of resources for vector control, incorporating evidence-based decision-making, collaboration across sectors, and community participation (Beier et al., 2008; Shiff, 2002). Recent advancements in malaria vaccine development, including pre-erythrocytic and transmission-blocking vaccines, offer promising tools to complement vector control measures (Wang et al., 2009; Draper et al., 2018). Combining these vaccines with IVM strategies can enhance the overall effectiveness of malaria control programs by targeting both the mosquito vectors and the malaria parasites at different stages of their life cycle (Kaslow et al., 2017).

5.2 Policy and implementation

Effective policy and implementation are crucial for the success of integrated malaria control strategies. Policies should promote the integration of vector management and vaccination within national malaria control programs, ensuring that resources are allocated efficiently and interventions are tailored to local contexts (Karunamoorthi, 2011; Benelli and Beier, 2017). The World Health Organization (WHO) has endorsed IVM as a global strategy for controlling vector-borne diseases, highlighting the importance of inter-sectoral collaboration, capacity-building, and community engagement (Beier et al., 2008). Successful implementation requires continuous monitoring and evaluation of vector control programs, as well as the development of innovative tools and approaches to address emerging challenges such as insecticide resistance and environmental changes (Kaslow et al., 2017; Wilson et al., 2020).

5.3 Community involvement

Community involvement is a cornerstone of integrated malaria control. Engaging communities in the planning, implementation, and evaluation of vector management and vaccination programs can significantly enhance their effectiveness and sustainability (Asale et al., 2019; Ng’ang’a et al., 2021). Community-based education and mobilization efforts have been shown to improve treatment-seeking behavior, increase the use of preventive measures such as insecticide-treated nets (ITNs), and reduce malaria transmission (Asale et al., 2019). For example, in western Kenya, community participation in IVM activities, including the distribution of educational materials and the establishment of income-generating activities like fish farming, has led to significant reductions in malaria cases and increased community awareness (Figure 2) (Ng’ang’a et al., 2021). Similarly, in southwestern Ethiopia, coordinated community-based interventions have contributed to a substantial decline in malaria incidence (Asale et al., 2019).

By integrating vector management and vaccination, developing supportive policies, and actively involving communities, malaria control programs can achieve more comprehensive and lasting impacts in the fight against malaria.

6 Global and Regional Perspectives

6.1 Global trends in malaria control

Malaria control has seen significant advancements over the past few decades, driven by a combination of vector control, improved diagnostics, and the development of vaccines. Vector control remains a cornerstone of malaria elimination efforts, particularly in the absence of highly effective vaccines and the emergence of drug-resistant strains of the parasite (Karunamoorthi, 2011; Kaslow et al., 2017). Integrated Vector Management (IVM) has been emphasized as a comprehensive approach to control mosquito populations, combining various strategies such as indoor residual spraying (IRS), long-lasting insecticidal nets (LLINs), and environmental management (Raghavendra et al., 2011; Benelli and Beier, 2017). The global malaria vaccine pipeline is robust, with numerous candidates in various stages of development, including the RTS,S vaccine, which has shown partial efficacy in clinical trials (Crompton et al., 2010; Hemingway et al., 2016). Despite these advancements, the global fight against malaria faces challenges such as insecticide resistance, the need for new diagnostic tools, and the development of more effective vaccines (Benelli and Mehlhorn, 2016; Kaslow et al., 2017).

6.2 Regional case studies

6.2.1 Sub-Saharan Africa

Sub-Saharan Africa remains the region most affected by malaria, with children and pregnant women being particularly vulnerable. The region has seen some success with the implementation of IRS and LLINs, but these methods have not significantly reduced malaria prevalence due to outdoor transmission and insecticide resistance (Benelli and Beier, 2017). The RTS,S vaccine is currently being evaluated in phase III trials in Africa, showing partial protection against malaria (Crompton et al., 2010). However, the region still requires new vector control tools and strategies to address these challenges effectively (Benelli and Mehlhorn, 2016).

6.2.2 Southeast Asia

In Southeast Asia, the emergence of artemisinin-resistant strains of Plasmodium falciparum poses a significant threat to malaria control efforts. The region has focused on the development and deployment of new drugs and combination therapies to combat drug resistance (Kaslow et al., 2017). Additionally, innovative vector control measures, such as the use of biological control agents and genetic manipulation of mosquito populations, are being explored to reduce transmission (Raghavendra et al., 2011).

6.2.3 Latin America

Latin America has made considerable progress in reducing malaria incidence through a combination of vector control and active case management. However, the region faces challenges such as the reintroduction of malaria in areas where it was previously eliminated and the need for sustained political and financial commitment to maintain control efforts (Karunamoorthi, 2011; Hemingway et al., 2016). The recent outbreaks of other mosquito-borne diseases, such as Zika and dengue, have also highlighted the need for integrated vector management strategies that address multiple diseases simultaneously (Benelli and Mehlhorn, 2016).

6.3 Challenges in different regions

Different regions face unique challenges in malaria control, necessitating tailored approaches to address these issues effectively. In Africa, the primary challenges include insecticide resistance, outdoor transmission, and the need for new vector control tools (Benelli and Beier, 2017). Southeast Asia grapples with drug-resistant malaria strains and requires new therapeutic options and combination therapies (Kaslow et al., 2017). Latin America must focus on maintaining the gains achieved in malaria control and addressing the threat of reintroduction in previously malaria-free areas (Karunamoorthi, 2011; Hemingway et al., 2016). Additionally, the emergence of other mosquito-borne diseases in various regions underscores the importance of integrated vector management strategies that can address multiple public health threats simultaneously (Benelli and Mehlhorn, 2016).

In conclusion, while significant progress has been made in malaria control globally, regional challenges persist that require innovative solutions and sustained efforts. The development of new vector control tools, effective vaccines, and integrated management strategies will be crucial in overcoming these challenges and achieving the goal of malaria elimination and eventual eradication.

7 Future Directions in Malaria Control

7.1 Emerging technologies

The future of malaria control hinges on the development and implementation of emerging technologies. Recent advancements in vector control, such as the use of genetic manipulation and sterile insect techniques, show promise in reducing malaria transmission. These methods, which include the use of evolution-proof insecticides like fungal biopesticides, Wolbachia, and Denso virus, are designed to manipulate the mosquito life cycle and reduce vector populations effectively (Raghavendra et al., 2011). Additionally, innovative diagnostic tools and next-generation vector control products are in the pipeline, with many expected to be introduced in the next decade (Hemingway et al., 2016). The integration of these new technologies with existing methods could significantly enhance the efficacy of malaria control programs.

7.2 Research priorities

Research priorities in malaria control should focus on overcoming the challenges posed by drug and insecticide resistance. The development of highly efficacious vaccines remains a critical area of research. Despite the complexity of the malaria parasite, recent progress in vaccine development, including the creation of partially effective recombinant pre-erythrocytic subunit vaccines and live-attenuated sporozoite vaccines, offers hope for future breakthroughs (Wang et al., 2009; Draper et al., 2018). Furthermore, research should aim to improve the deployment and use of existing tools, such as insecticide-treated mosquito nets and artemisinin-based combination treatments, to maximize their impact (Guérin et al., 2002). Understanding the host-parasite interaction at a molecular level could also lead to novel vaccine designs and more effective control strategies (Healer et al., 2017).

7.3 Funding and policy support

Sustained funding and robust policy support are essential to achieving global malaria eradication. The development and adoption of new tools and strategies require significant financial investment and political commitment. International donors and national governments must be provided with cost-benefit information to justify increased support for malaria control initiatives (Guérin et al., 2002). Additionally, effective inter-sectoral coordination and community participation are crucial for the successful implementation of integrated vector management methods (Raghavendra et al., 2011). Continued financial and political commitment will ensure the rapid uptake of new technologies and the maintenance of gains achieved in malaria control (Hemingway et al., 2016).

By focusing on these future directions, the global community can make significant strides towards the ultimate goal of malaria elimination and eradication.

8 Concluding Remarks

Over the past decade, significant strides have been made in the fight against malaria, particularly in the areas of vector management and vaccine development. The product development pipeline for malaria has never been stronger, with numerous innovative tools being developed to detect, treat, and prevent malaria. These include advanced diagnostics, new medicines, vaccines, and vector control products. Integrated Vector Management (IVM) has been globally adopted and has shown promise in optimizing resource use for vector control through evidence-based decision-making, integrated approaches, and capacity-building. Additionally, the development of novel vaccine candidates, such as the RTS,S vaccine, has provided partial protection and is currently undergoing further evaluation. The introduction of new vector control agents, such as insect growth regulators and biocontrol agents, has also shown potential in reducing malaria transmission.

Despite these advances, challenges remain in achieving malaria elimination. The development of new diagnostics, drugs, and vaccines is essential to overcome existing resistance and protect against severe disease. Future research should focus on optimizing vector control strategies, including the development of eco-friendly tools and the careful evaluation of their field efficacy. The integration of new and existing approaches tailored to different settings will be crucial to maximize their effectiveness and longevity. Additionally, understanding the ecological and behavioral aspects of malaria vectors will be vital in developing more effective control measures. Continued financial and political commitment, along with intensified mechanisms for information management and surveillance, will be necessary to sustain progress towards malaria eradication.

To achieve the goal of malaria elimination, a concerted effort is required from all stakeholders. National malaria control programs should strengthen their capacity to use data for decision-making and employ additional vector control tools in conjunction with existing strategies. There is a need for continued research to identify and evaluate new tools for vector control that can be integrated with existing biomedical strategies. Collaboration among different disciplines, including parasitology, tropical medicine, ecology, and entomology, is essential to ensure the proper evaluation of novel control strategies. Furthermore, global health initiatives should prioritize the development and deployment of highly effective vaccines and support the implementation of mass vaccination programs in endemic regions. By working together, we can build on the progress made and move closer to a world free of malaria.

Acknowledgments

I would like to express our gratitude to the two anonymous peer researchers for their constructive suggestions on our manuscript.

Conflict of Interest Disclosure

The author affirms that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.

References

Arora N., Anbalagan L., and Pannu A., 2021, Towards eradication of malaria: is the WHO's RTS,S/AS01 vaccination effective enough? Risk Management and Healthcare Policy, 14: 1033-1039.

https://doi.org/10.2147/RMHP.S219294

PMid:33737844 PMCid:PMC7966294

Asale A., Kussa D., Girma M., Mbogo C., and Mutero C., 2019, Community based integrated vector management for malaria control: lessons from three years' experience (2016-2018) in Botor-Tolay district, southwestern Ethiopia, BMC Public Health, 19: 1-14.

https://doi.org/10.1186/s12889-019-7606-3

PMid:31638928 PMCid:PMC6805624

Beier J., Keating J., Githure J., Macdonald M., Impoinvil D., and Novak R., 2008, Integrated vector management for malaria control, Malaria Journal, 7: S4.

https://doi.org/10.1186/1475-2875-7-S1-S4

PMid:19091038 PMCid:PMC2604879

Benelli G., and Beier J., 2017, Current vector control challenges in the fight against malaria, Acta tropica, 174: 91-96.

https://doi.org/10.1016/j.actatropica.2017.06.028

PMid:28684267

Benelli G., and Mehlhorn H., 2016, Declining malaria, rising of dengue and Zika virus: insights for mosquito vector control, Parasitology Research, 115: 1747-1754.

https://doi.org/10.1007/s00436-016-4971-z

PMid:26932263

Chaccour C., Alonso S., Zulliger R., Wagman J., Saifodine A., Candrinho B., Macete E., Brew J., Fornadel C., Kassim H., Loch L., Sacoor C., Varela K., Carty C., Robertson M., and Saute F., 2018, Combination of indoor residual spraying with long-lasting insecticide-treated nets for malaria control in Zambezia, Mozambique: a cluster randomised trial and cost-effectiveness study protocol, BMJ Global Health, 3(1): e000610.

https://doi.org/10.1136/bmjgh-2017-000610

PMid:29564161 PMCid:PMC5859815

Crompton P., Pierce S., and Miller L., 2010, Advances and challenges in malaria vaccine development, The Journal of Clinical Investigation, 120(12): 4168-4178.

https://doi.org/10.1172/JCI44423

PMid:21123952 PMCid:PMC2994342

Dhanawat M., Das N., Nagarwal R., and Pandit J., 2010, Development in malarial vaccine: A review, Drug discoveries & therapeutics, 4(5): 298-313.

Draper S., Sack B., King C., Nielsen C., Rayner J., Higgins M., Long C., and Seder R., 2018, Malaria vaccines: recent advances and new horizons, Cell Host & Microbe, 24: 43-56.

https://doi.org/10.1016/j.chom.2018.06.008

PMid:30001524 PMCid:PMC6054918

Guérin P., Olliaro P., Nosten F., Druilhe P., Laxminarayan R., Binka F., Kilama W., Ford N., and White N., 2002, Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development, The Lancet, Infectious diseases, 2(9): 564-573.

https://doi.org/10.1016/S1473-3099(02)00372-9

PMid:12206972

Healer J., Cowman A., Kaslow D., and Birkett A., 2017, Vaccines to accelerate malaria elimination and eventual eradication, Cold Spring Harbor perspectives in medicine, 7: 9.

https://doi.org/10.1101/cshperspect.a025627

PMid:28490535 PMCid:PMC5580511

Hemingway J., Shretta R., Wells T., Bell D., Djimde A., Achee N., and Qi G., 2016, Tools and strategies for malaria control and elimination: what do we need to achieve a grand convergence in malaria? PLoS Biology, 14(3): e1002380.

https://doi.org/10.1371/journal.pbio.1002380

PMid:26934361 PMCid:PMC4774904

Holder A., 1990, Malaria vaccines, Science, 248(4954): 422.

https://doi.org/10.1126/science.248.4954.422-c

Karunamoorthi K., 2011, Vector control: a cornerstone in the malaria elimination campaign, Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 17(11): 1608-1616.

https://doi.org/10.1111/j.1469-0691.2011.03664.x

PMid:21996100

Kaslow D., Okumu F., Wells T., Rabinovich R., Bassat Q., Birkett A., Sauerwein R., Slutsker L., and Vekemans J., 2017, malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication, PLoS Medicine, 14(11): e1002455.

https://doi.org/10.1371/journal.pmed.1002455

PMid:29190291 PMCid:PMC5708606

Mahmoudi S., and Keshavarz H., 2017, Efficacy of phase 3 trial of RTS, S/AS01 malaria vaccine in infants: a systematic review and meta-analysis, Human vaccines & immunotherapeutics, 13: 2098-2101.

https://doi.org/10.1080/21645515.2017.1295906

PMid:28272979 PMCid:PMC5612527

Nadeem A., Shehzad A., Islam S., Al-Suhaimi E., and Lee Y., 2022, Mosquirix™ RTS, S/AS01 vaccine development, immunogenicity, and efficacy, Vaccines, 10(5): 713.

https://doi.org/10.3390/vaccines10050713

PMid:35632469 PMCid:PMC9143879

Ng'ang'a P., Aduogo P., and Mutero C., 2021, Strengthening community and stakeholder participation in the implementation of integrated vector management for malaria control in western Kenya: a case study, Malaria Journal, 20: 1-14.

https://doi.org/10.1186/s12936-021-03692-4

PMid:33740983 PMCid:PMC7977174

Nikolaeva D., Draper S., and Biswas S., 2015, Toward the development of effective transmission-blocking vaccines for malaria, Expert Review of Vaccines, 14: 653-680.

https://doi.org/10.1586/14760584.2015.993383

PMid:25597923

Ogeto T., Ndubi F., Murithi M., Kagia R., Wambugu E., Suge T., Chepkirui C., Tonui J., Maiyo F., Momanyi L., and Walekhwa M., 2020, Malaria vaccines targeting the pre-erythrocytic stage: a scoping review, F1000Research, 9: 680.

https://doi.org/10.12688/f1000research.24320.1

Olotu A., Urbano V., Hamad A., Eka M., Chemba M., Nyakarungu E., Raso J., Eburi E., Mandumbi D., Hergott D., Maas C., Ayekaba M., Milang D., Rivas M., Schindler T., Embon O., Ruben A., Saverino E., Abebe Y., Kc N., James E., Murshedkar T., Manoj A., Chakravarty S., Li M., Adams M., Schwabe C., Segura J., Daubenberger C., Tanner M., Tanner M., Richie T., Billingsley P., Sim B., Abdulla S., and Hoffman S., 2017, Advancing global health through development and clinical trials partnerships: a randomized, placebo-controlled, double-blind assessment of safety, tolerability, and immunogenicity of pfspz vaccine for malaria in healthy equatoguinean men, The American Journal of Tropical Medicine and Hygiene, 98: 308-318.

https://doi.org/10.4269/ajtmh.17-0449

PMid:29141739 PMCid:PMC5928718

Pluess B., Tanser F., Lengeler C., and Sharp B., 2010, Indoor residual spraying for preventing malaria, The Cochrane database of systematic reviews, 4: CD006657.

https://doi.org/10.1002/14651858.CD006657.pub2

PMid:20393950 PMCid:PMC6532743

Protopopoff N., Wright A., West P., Tigererwa R., Mosha F., Kisinza W., Kleinschmidt I., and Rowland M., 2015, Combination of insecticide treated nets and indoor residual spraying in northern Tanzania provides additional reduction in vector population density and malaria transmission rates compared to insecticide treated nets alone: a randomised control trial, PLoS ONE, 10(11): e0142671.

https://doi.org/10.1371/journal.pone.0142671

PMid:26569492 PMCid:PMC4646432

Pryce J., Medley N., and Choi L., 2022, Indoor residual spraying for preventing malaria in communities using insecticide‐treated nets, The Cochrane Database of Systematic Reviews, (1).

https://doi.org/10.1002/14651858.CD012688.pub3

PMid:35038163 PMCid:PMC8763033

Raghavendra K., Barik T., Reddy B., Sharma P., and Dash A., 2011, Malaria vector control: from past to future, Parasitology Research, 108: 757-779.

https://doi.org/10.1007/s00436-010-2232-0

PMid:21229263

Regules J., Cicatelli S., Bennett J., Paolino K., Twomey P., Moon J., Kathcart A., Hauns K., Komisar J., Qabar A., Davidson S., Dutta S., Griffith M., Magee C., Wojnarski M., Livezey J., Kress A., Waterman P., Jongert E., Wille-Reece U., Volkmuth W., Emerling D., Robinson W., Lievens M., Morelle D., Lee C., Yassin-Rajkumar B., Weltzin R., Cohen J., Paris R., Waters N., Birkett A., Kaslow D., Ballou W., Ockenhouse C., and Vekemans J., 2016, Fractional third and fourth dose of RTS,S/AS01 malaria candidate vaccine: a phase 2a controlled human malaria parasite infection and immunogenicity study, The Journal of infectious diseases, 214(5): 762-771.

https://doi.org/10.1093/infdis/jiw237

PMid:27296848

Seidlein L., Hanboonkunupakarn B., Jittamala P., Pongsuwan P., Chotivanich K., Tarning J., Hoglund R., Winterberg M., Mukaka M., Peerawaranun P., Sirithiranont P., Doran Z., Ockenhouse C., Ivinson K., Lee C., Birkett A., Kaslow D., Singhasivanon P., Day N., Dondorp A., White N., and Pukrittayakamee S., 2019, Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers, Human Vaccines & Immunotherapeutics, 16: 33-41.

https://doi.org/10.1080/21645515.2019.1643675

PMid:31306084 PMCid:PMC7012096

Shiff C., 2002, Integrated approach to malaria control, Clinical Microbiology Reviews, 15: 278-293.

https://doi.org/10.1128/CMR.15.2.278-293.2002

PMid:11932233 PMCid:PMC118067

Theisen M., Jore M., and Sauerwein R., 2017, Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine, Expert Review of Vaccines, 16: 329-336.

https://doi.org/10.1080/14760584.2017.1276833

PMid:28043178

Valéa I., Adjei S., Usuf E., Traoré O., Ansong D., Tinto H., Boateng H., Leach A., Some A., Buabeng P., Vekemans J., Nana L., Kotey A., Vandoolaeghe P., Ouedraogo F., Sambian D., Lievens M., Tahita M., Rettig T., Jongert E., Lompo P., Idriss A., Borys D., Ouédraogo S., Prempeh F., Habib M., Schuerman L., Sorgho H., and Agbenyega T., 2018, Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial, Human Vaccines & Immunotherapeutics, 14: 1489-1500.

https://doi.org/10.1080/21645515.2018.1442996

PMid:29630438 PMCid:PMC6037440

Wagman J., Varela K., Zulliger R., Saifodine A., Muthoni R., Magesa S., Chaccour C., Gogue C., Tynuv K., Seyoum A., Dengela D., Saute F., Richardson J., Fornadel C., Linton Y., Slutsker L., Candrinho B., and Robertson M., 2021, Reduced exposure to malaria vectors following indoor residual spraying of pirimiphos-methyl in a high-burden district of rural Mozambique with high ownership of long-lasting insecticidal nets: entomological surveillance results from a cluster-randomized trial, Malaria Journal, 20: 1-17.

https://doi.org/10.1186/s12936-021-03583-8

PMid:33478533 PMCid:PMC7819201

Wang R., Smith J., and Kappe S., 2009, Advances and challenges in malaria vaccine development, Expert Reviews in Molecular Medicine, 11: e39.

https://doi.org/10.1017/S1462399409001318

PMid:20003658 PMCid:PMC2943423

Wilby K., Lau T., Gilchrist S., and Ensom M., 2012, Mosquirix (RTS,S): a novel vaccine for the prevention of Plasmodium falciparum malaria, Annals of Pharmacotherapy, 46: 384-393.

https://doi.org/10.1345/aph.1Q634

PMid:22408046

Wilson A., Courtenay O., Kelly-Hope L., Scott T., Takken W., Torr S., and Lindsay S., 2020, The importance of vector control for the control and elimination of vector-borne diseases, PLoS Neglected Tropical Diseases, 14(1): e0007831.

https://doi.org/10.1371/journal.pntd.0007831

PMid:31945061 PMCid:PMC6964823